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Abstracts / Biol Blood Marrow Transplant 19 (2013) S211eS232S228chemotherapy was HIDAC (1-3 grams/m2 for 6-8 doses)/
Etoposide(15-40mg/kg) in 16 patients and growth factor
alone in one patient. Median time from diagnosis to ASCT
was 4.2 (range 3.6-7) months. Preparative regimen for ASCT
was Busulfan (3.2mg/kg x 4)/Etoposide (60 mg/kg) in 12
patients and high dose melphalan in 5 patients. The median
CD34 cells infused was 4.9 x 10e6/kg (range 2.8 to 15.9).All
patients engrafted with a median time to neutrophil
engraftment of 11 (range10-12) days. The median time to
platelet engraftment was 20 (range15-40) days. The median
length of inpatient stay during the ASCT admission was 14
(range 10-25) days. One patient died of progressive disease
14 months post ASCT. Two patients died in remission on day
53 (sepsis) and day 836 (unknown cause) post ASCT. Four-
teen patients (82%) are currently alive in complete remission.
at a median follow-up of 20 (range 1- 40) months post ASCT.
Conclusion: Consolidation of good risk AML patients with
ASCT following induction of complete remission is safe and
effective in preventing relapse in good risk AML patients.232
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In many cases the only curative treatment option for
patients with advanced leukemias may be hematopoietic cell
transplantation (HCT), which is often associated with toxic-
ities. Despite HCT, patients still relapse while others will not
have the option of HCT due to the unavailability of an HLA-
matched donor. We aim to overcome these hurdles using
anti-CD45 pretargeted radioimmunotherapy (PRIT) in lieu of
total body irradiation (TBI) for haploidentical bone marrow
transplantation (BMT). B6SJLF1/J mice were given 105
syngeneic myeloid leukemia cells followed by injection of
anti-CD45 antibody (30F11; 140 mg) conjugated to strepta-
vidin (SAv). Eight hours later a biotinylated synthetic clearing
agent (CA) (50 mg) was injected, followed by 90Y-labeled
DOTA- (2 mg) 2 hours later. This strategy resulted in excellent
localization of radioactivity in spleen [38.1  7.3 percent of
the injected dose of radioactivity per gram of organ (% ID/g)]
and bonemarrow (BM; 3.41.1% ID/g), withminimal uptake
in non-target organs (kidneys, 0.70 0.13% ID/g; lungs, 0.3
0.1% ID/g) 24 hours after radiobiotin injection. In separate
BMT studies, mice were treated with and without ﬂudar-
abine (FLU) (100 mg/kg/day) on days -8 to -4, and/or cyclo-
phosphamide (CY; 200 mg/kg/day) on days -2 and +2, and
30F11-SAv (140 mg) followed by CA (50 mg) and 400-800 mCi
of 90Y-DOTA-biotin three days prior to infusion of 15x106 BM
cells from haploidentical donor mice (CB6F1/J, H-2Dd). In
mice transplanted without TBI but using 800 mCi of 90Y-
DOTA-biotin, day 28 ﬂow cytometry analysis detected up to
12% donor CD8+ cells, with no reduction in levels ofchimerism in the absence of FLU or CY. Subsequently, mice
with disseminated syngeneic leukemia treated with the PRIT
approach in the absence of FLU and TBI showed an
improvement inmedian survival (OS) compared to untreated
leukemic mice (see FIGURE). Mice treated with 400-800 mCi
of 90Y-DOTA-biotin had a median OS of at least 50 days
compared to a median OS of 23 days in untreated control
mice. Forty percent of mice given 800 mCi of 90Y-DOTA-biotin
died early from complications from BM aplasia. These results
suggest that anti-CD45 PRIT can localize radiation effectively
to BM and spleen, and when used in conjunction with hap-
loidentical BMT without TBI or FLU, can facilitate engraft-
ment and lead to improvements in OS in a disseminated
murine leukemia model.
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Equal for Children with Acute Lymphoblastic Leukemia
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Allogeneic hematopoietic stem-cell transplantation
(HSCT) from HLA identical sibling donors is standard of care
for children with high-risk acute lymphoblastic leukemia
